{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-26-000107","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2026-07-13T20:25:14+00:00","discovered_at":"2026-07-13T20:26:00.469072+00:00","generated_at":"2026-07-13T20:26:08.632960+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Pliant Therapeutics appoints two new independent directors, expands board to nine","bullets":["Board size increased from 7 to 9; Robert Iannone, M.D. and Flavia Borellini, Ph.D. appointed as Class I and Class II directors respectively.","Iannone joins R&D Committee; Borellini appointed chair of R&D Committee.","Each new director receives annual retainer of $40,000, plus committee fees; each granted option for 60,000 shares vesting over 3 years.","Both directors determined independent under SEC and Nasdaq rules; no material transactions with company."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-26-000107","json":"https://secwatch.observer/filing/0001746473-26-000107.json","markdown":"https://secwatch.observer/filing/0001746473-26-000107.md","text":"https://secwatch.observer/filing/0001746473-26-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/0001746473-26-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/plrx-20260709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T20:26:08.632960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}